Methodological options for setting the health benefits package

Peter C. Smith
Imperial College London and University of York
Purpose of this session

• To explain the role, the strengths and the limitations of analytic methods in informing the specification of the health benefits package

• Not intended as a methods tutorial
Outline of methods session

1. Introductory remarks – methods in context
2. Cost-effectiveness analysis
   – Measurement of health benefits
   – Measurement of costs
   – The cost-effectiveness threshold
3. Extended cost-effectiveness analysis
4. Assessment of evidence relevance and limitations
5. Setting analytic priorities
“Nobody knew that healthcare could be so complicated.”

Donald J. Trump, 27 February 2017
Ten Core Elements of Setting a Health Benefits Package

1. Set goals & criteria
2. Operationalize general criteria & define methods for appraisal
3. Choose “shape” of HBP & select areas for further analysis
4. Collate existing & collect new evidence
5. Undertake appraisals & budget impact assessment
6. Deliberate around evidence/appraisals
7. Make recommendations, take decisions
8. Translate decisions into resource allocation & use
9. Manage & implement HBP
10. Review, learn, revise

CONTEXT
- Donors
- Health system
- Markets
- Political institutions
- Regime
- Rights
- Technology
- Wealth

Three dimensions to consider when moving towards universal coverage.

The role of analytic methods in informing the HBP

• Creation of HBP serious issue, with consequences for the health, life prospects and finances of affected individuals
• Ultimately a profound political problem
• Analytic methods can contribute by:
  – Acting as a ‘referee’ between competing claims for limited resources
  – Protecting politicians and other policy makers from impossible demands of competing claims for health services
  – Clarifying priorities and trade-offs (e.g. equity)
  – Facilitating accountability, transparency and consistency
  – Using evidence to best effect
  – Focusing attention where it is most needed
  – Demonstrating that health service funds are spent wisely
Analytic methods in context

• Should always be informed by legitimate policy choices
• Their key role is to apply chosen criteria consistently and universally
• Methods seek to maximize the ‘value’ obtained from limited health system resources
• Transparency should be intrinsic to analysis
• Recognize limitations to data, research and analytic capacity
• Analytic evidence should always be considered alongside other contextual evidence and constraints.
Key choices when applying analytic methods

• What is ‘value’?
  – Health
  – Financial protection
  – Other

• What are available resources?

• What are other constraints to choices?

• How is ‘equity’ to be interpreted?
The key concept of ‘opportunity cost’

• Whatever methods are used, some groups will gain (from inclusions in the HBP) and others will lose (through exclusions from the HBP)

• Gains from inclusions may be reflected in:
  – health (access to services that would not otherwise have been available)
  – finance (zero charges for services that would otherwise be charged for)

• These gains must be compared with the opportunity costs for those whose medical needs are excluded from the HBP
2. Cost-effectiveness analysis (CEA)

- Based on the principle of *constrained maximization* of benefits with respect to a fixed budget
- Seeking to capture the *incremental* costs and benefits of a health service intervention
- So must always evaluate with respect to a *comparator* (which may often be ‘do nothing’)
- Usually assumes interventions are *independent* of each other
- The *incremental cost-effectiveness ratio* (ICER) is a key metric for any intervention
- Interventions are *ranked* according to their ICERs, and included until the budget is exhausted
- Resources:
CEA – Measuring benefits

- Challenging to model lifetime health gains, but methods well developed for many NCDs; increasing use for infectious diseases
- Generally accepted principles of quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs)
  - Life expectancy
  - Health-related quality of life
- Have to make some assumption about ‘quality’ of the intervention (effectiveness of service delivery)
- Health gains to identical individuals should be similar whatever the health system (subject to similar service quality) so benefits calculations often transferrable between settings
- Special challenges for infectious diseases
  - Externalities
  - Dependent on epidemiology, behaviour etc
What are DALYs trying to show #1: Acute intervention at age $a$
What are DALYs trying to show #2: Preventive intervention at age $a$
CEA – Measuring costs

• In principle should seek out opportunity costs
• Accounting costs usually used as a proxy
• Cost structures complex for many health services
  – Much early CEA work on pharmaceuticals, for which infrastructure costs relatively low
  – Infrastructure costs shared by many interventions
  – Economies of scale and scope
  – Often highly dependent on local service organization, so may not be readily transferrable between settings
• Costing tools beginning to emerge:
  – WHO OneHealth http://www.who.int/choice/onehealthtool/en/
• Costing also essential for
  – calculating budget impact
  – pricing and provider payment
CEA – the cost-effectiveness threshold

• The threshold indicates the ICER (cost per DALY) of the marginal intervention, just included in the HBP
• Any intervention with a higher ICER should be excluded
• The level of the threshold depends on epidemiology, budget availability, and the range of therapies under consideration
• The threshold is useful because it acts as a rigorous rule of thumb for considering interventions piecemeal, not requiring re-assessment of the entire HBP
• The level of the threshold may change (reduce) if a treatment with high budget impact is introduced into the HBP
Non-budgetary constraints in CEA (Hauck, Thomas and Smith chapter)

• Six categories of impediment to implementing CEA recommendations:
  – Design of the health system (eg human resource constraints)
  – Costs of implementing change
  – System interdependencies between interventions (eg shared platforms)
  – Uncertainty
  – Weak governance
  – Political constraints
Quantifying and handling uncertainty in CEA

• Uncertainty intrinsic to all analysis
• Can arise from numerous sources:
  – Limitations in evidence from cost-effectiveness studies (e.g. sample size; target population; country setting; date of study)
  – Limitations in modelling methods used (model structure, parameters used)
  – Uncertainty about effectiveness with which health services will be delivered
  – Uncertainty about which population groups will use the treatment and heterogeneity in their benefits or costs
• Increasingly sophisticated methods for modelling and presenting uncertainty
• Often an important factor in decision-making, especially when deferral of decision is possible

3. Extended CEA  
(Verguet and Jamison chapter)

• Extends the principle of conventional CEA to reflect (a) equity and (b) financial protection
• Calculates measures of financial loss averted by including the treatment in the HBP
• Reports health gains and financial gains by income group
• Leaves reporting disaggregated to allow decision-makers to take the different outcomes into account – does not seek to summarize benefits
Table 2. Extended cost-effectiveness analysis (ECEA) results for universal public finance of tuberculosis treatment to 40 + 10% coverage (per 1,000,000 population).

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Total</th>
<th>Income Quintile I</th>
<th>Income Quintile II</th>
<th>Income Quintile III</th>
<th>Income Quintile IV</th>
<th>Income Quintile V</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB deaths averted</td>
<td>90</td>
<td>36</td>
<td>27</td>
<td>18</td>
<td>9</td>
<td>0</td>
</tr>
<tr>
<td>Private expenditures averted</td>
<td>40,000</td>
<td>16,000</td>
<td>12,000</td>
<td>8,000</td>
<td>4,000</td>
<td>0</td>
</tr>
<tr>
<td>Poverty cases averted</td>
<td>34</td>
<td>34</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Examining the efficient purchase of health, equity, and non-health benefits, we find: $ICER = \$520$ per death averted, $ICER_{FRP} = \$1,470$ per poverty case averted, and $ICER_{Eq} = \$125,000$ per equity ratio (when simple metric of the ratio between the health benefits among the poorest and the total sum of the health benefits is used). Scaling per $\$1,000,000$ spent, we obtain 1,800 deaths averted, 720 of which among the bottom income quintile, and 680 poverty cases averted, all of which among the bottom income quintile.
4. Assessment of evidence relevance and limitations

Hawkins, Heggie and Wu chapter

• Increased interest in what constitutes ‘relevant’ evidence for CEA, and how it might be incorporated into creation of the HBP

• Relevance might be related to:
  – Treatment under scrutiny and its comparator
  – Quality of study
  – Population group
  – Geography
  – Date of study
  – Health system setting

• General principle is to allow all ‘relevant’ evidence to inform decision
Analytic approaches towards assessment of evidence

• Systematic reviews and searches
  – Eg snowballing; pearl growing
• Assessment of internal and external validity
  – validity testing tools eg EVAT external validity assessment tool
• Meta-analysis and other aggregation tools
• Sensitivity analysis
• ‘Value of information’ analysis
  – Identifying priorities for new or augmented data
• Creating evidence
  – Commissioning research
  – Monitoring and evaluation after implementation
5. Setting analytic priorities

• Limited local analytic capacity
• Need to prioritize topics
  – Always political priority topics!
  – But also topics where the budget impact is large
  – ... or the cost-effectiveness is close to your likely threshold
• In principle, treatments currently in the HBP but candidates for exclusion should also be considered
• New evidence may prompt reconsideration
• New research studies
• Assessing monitoring evidence from implementation
Towards standardizing CEA – the international reference case

• Principles of Economic Evaluation
  – Transparency
  – Comparators
  – Use of Evidence
  – Measure of outcome
  – Measurement of costs
  – Time horizon for costs and effects
  – Costs and Effects outside health
  – Heterogeneity
  – Uncertainty
  – Impact on other constraints and budget impact
  – Equity implications

Tommy Wilkinson, Kalipso Chalkidou, Karl Claxton, Paul Revill, Mark Sculpher, Andrew Briggs, Yot Teerawattananon, Waranya Rattanavipapong

Contribution of methods to creation of the HBP

• Clarify nature of choices to be made
• Make political preferences operational
• Create a ‘level playing field’ for patients, providers and manufacturers
• Promote consistency, transparency and stability
• Synthesize available evidence
• Identify priorities for new evidence
• Maximize ‘value’ secured from health system
• Promote confidence that health system finances are spent wisely
Acknowledgements

• Amanda Glassman, Ursula Giedion, Kalipso Chalkidou, Tommy Wilkinson, Paul Revill, Laura Downey

• Book chapter authors:
  – Mark Sculpher; Paul Revill; Jessica Ochalek; Karl Claxton; Cheryl Cashin; Annette Özaltın; Alec Morton; Jeremy A. Lauer; Stéphane Verguet; Dean T. Jamison; Katharina Hauck; Ranjeeta Thomas; Neil Hawkins; Robert Heggie; Olivia Wu

• Commentaries
  – Gerald Manthalu; Dominic Nkhoma; Jessica Ochalek; Andrew Phillips; Paul Revill; Yot Teerawattananon; Nattha Tritasavit; Sitaporn Youngkong; Suradech Doungthipsirikul; Tran Thi Mai Oanh; Khuong Anh Tuan; Nguyen Khanh Phuong; Waranya Rattanavipapong

• International Decision Support Initiative (iDSI)
  – funded by the Bill & Melinda Gates Foundation, the UK Department for International Development..